Código QR

Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature

IntroductionAs the global pandemic continues, new complications of COVID-19 in pediatric population have turned up, one of them being hemolytic uremic syndrome (HUS), a complement-mediated thrombotic microangiopathy (CM-TMA) characterized by triad of thrombocytopenia, microangiopathic hemolytic anem...

Descrición completa

Gardado en:
Principais autores: Matija Matošević, Ivanka Kos, Maša Davidović, Maja Ban, Hana Matković, Ivan Jakopčić, Ivana Vuković Brinar, Ágnes Szilágyi, Dorottya Csuka, György Sinkovits, Zoltán Prohászka, Kristina Vrljičak, Lovro Lamot
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pediatrics
Assuntos:
hemolytic uremic syndrome
HUS
thrombotic microangiopathy
TMA
COVID-19
complement blockade
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fped.2023.1092860/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares